ReviewPharmacy (Basel, Switzerland)2020
A Role for Primary Care Pharmacists in the Management of Inflammatory Bowel Disease? Lessons from Chronic Disease: A Systematic Review.
Review in Pharmacy (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Adherence in the Treatment of Inflammatory Bowel Disease With Particular Focus on the Importance of the Clinical Pharmacist: A Systematic Review.Basic & clinical pharmacology & toxicology · 2025Pooled it
- A systematic review of the role of community pharmacists in the prevention and control of cardiovascular diseases: the perceptions of patients.Systematic reviews · 2023Pooled it
- Effects of the COVID-19 Pandemic on Physical Activity in Chronic Diseases: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2021Pooled it
- Impact of an intervention program on drug adherence in patients with ulcerative colitis: Randomized clinical trial.PloS one · 2023Trial
- Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab.Crohn's & colitis 360 · 2026Article
- Treatment of Irritable Bowel Syndrome With Antispasmolytics in Taiwan, Hong Kong, and Vietnam: A Delphi Expert Consensus Statement.Journal of neurogastroenterology and motility · 2025Article
- Healthcare Needs and Perceptions of People Living With Inflammatory Bowel Disease in Australia: A Mixed-Methods Study.Crohn's & colitis 360 · 2022Article
- Survey of Pharmacist-Led Medication Guidance for Patients with Inflammatory Bowel Disease in Japan.Inflammatory intestinal diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.